ME1
Pharmaceuticals, Biotechnology & Life Sciences
Melodiol Global Health
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 28 June 2024
- Reported shorts
- 592
- Shares on issue
- 194.092M
Melodiol Global Health (ME1) financials
Results, ratios and statements
Fundamentals
Our data providers hold no financial statements for ME1 (last checked 15 Oct 2026). The company's own filings are listed below.
Financial reports
The company's own filings, newest first
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2024via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2024via asx_announcements
- Annual Report to shareholdersAnnual Report28 Mar 2024via asx_announcements
- Preliminary Final ReportAnnual Results29 Feb 2024via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jan 2024via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2023via asx_announcements
- Half Yearly Report and AccountsHalf Year Results31 Aug 2023via asx_announcements
- Half Year Results CommentaryHalf Year Results31 Aug 2023via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2023via asx_announcements
- Mernova Delivers Record Half Yearly RevenuesHalf Year Results10 Jul 2023via asx_announcements
Showing 10 of 83 reports